-
Delving into the Details: Dr. Zhanhong Chen & Dr. Rui Ge on First-Line Treatment Options for HER2-Positive Breast Cancer
When it comes to the “P” in the THP regimen for HER2-positive breast cancer, do you prefer Pertuzumab or Pyrotinib? At the 2024 Breast Cancer Summer Forum · Northern Salon’s “Root Cause” session, Dr. Zhanhong Chen from Zhejiang Cancer Hospital and Dr. Rui Ge from Huadong Hospital Affiliated to Fudan University shared their perspectives. Professor…
-
Dr. Wenxing Qin: Advances in Research on Drug Resistance Mechanisms of ADCs in Breast Cancer
A century ago, Paul Ehrlich, the father of German immunology, proposed the concept of the “Magic Bullet,” which targets toxic drugs to microorganisms or tumor cells. With continuous technological breakthroughs, Antibody-Drug Conjugates (ADCs) have seen explosive approval. These drugs combine specific monoclonal antibodies with highly active cytotoxic drugs via linkers, balancing the specificity of targeted…
-
New Concepts in Regional Treatment of Breast Cancer and Future Outlook by Dr. Yongsheng Wang | 2024 CACA Integrated Breast Cancer Conference
At the 2024 China Anti-Cancer Association (CACA) Integrated Breast Cancer Conference, Dr. Yongsheng Wang from Shandong Cancer Hospital elaborated on new concepts in regional treatment for breast cancer. He emphasized that local regional treatment for breast cancer patients should comprehensively consider the risk of recurrence and metastasis, the efficacy and adverse effects of systemic treatment,…
-
Comprehensive Review of Chemotherapy-Induced Anemia Management in China （1）
Cancer-related anemia (CRA) encompasses anemia that occurs in cancer patients during disease progression or treatment, including non-chemotherapy-related CRA and chemotherapy-induced anemia (CIA). With the increase in chemotherapy treatments, the incidence of anemia is significant, with over 90% of patients not receiving any corrective treatment. To gain a comprehensive understanding of the current practices and perceptions…
-
CD7 CAR-T Combined with Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Improves Survival in r/r T-ALL/LBL Patients
Relapsed/refractory acute T-cell lymphoblastic leukemia/T-cell lymphoblastic lymphoma (r/r T-ALL/LBL) presents significant treatment challenges with poor prognosis. Data show that the 5-year survival rate is less than 25%, and even with salvage allo-HSCT, the 3-5 year survival rate is only 14-30%. Improving survival for these patients has become a hot research topic. Recently, Professor Xingyu Cao’s team…
-
The Next “Berlin Patient”? The 7th Global HIV Cure Case Emerges!
The “Berlin Patient” is renowned as the first person in the world to be cured of HIV, marking a significant milestone in medical history. Over a decade later, the pioneering team at Germany’s Charité – Universitätsmedizin Berlin has announced the successful treatment of the “Next Berlin Patient,” representing the 7th global case of HIV cure.…
-
SYK Inhibitors at EHA | Dr. Zeping Zhou: Mechanistic Insights into HMPL-523, a Promising SYK Inhibitor for ITP Treatment
The annual meeting of the European Hematology Association (EHA) is a premier international conference that gathers experts and scholars from around the globe to share and discuss innovative ideas and advancements in scientific and clinical research in the field of hematology. This year, the research on spleen tyrosine kinase (SYK) inhibitors has garnered significant attention.…
-
EHA International Perspectives丨Dr. Swaminathan Iyer: ELA026 Efficacy in Treatment-Naive mHLH Patients
Malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) is a highly aggressive and fatal disease, with innovative treatment strategies being a major focus and challenge in hematology research. Recently, ELA026—a novel monoclonal antibody targeting signal regulatory proteins (SIRP)-a/b1/g—has shown promising preliminary efficacy in clinical trials for treating mHLH. At the 29th European Hematology Association Annual Meeting (EHA 2024) held…
Connecting Medical Expertise through Media